<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03087175</url>
  </required_header>
  <id_info>
    <org_study_id>38RC15.311</org_study_id>
    <nct_id>NCT03087175</nct_id>
  </id_info>
  <brief_title>MGuard Stent and Microcirculation</brief_title>
  <acronym>GUARDIANCORY</acronym>
  <official_title>Impact of Polyethylene Terephthalate Micronet Mesh-Covered Stent (MGuard) on Coronary Microcirculation's Lesions in Patients With ST or Non ST-segment Elevation Myocardial Infarction (STE and NSTE-ACS): Assessment by Index of Microcirculatory Resistance (IMR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      NSTE-ACS represents the most frequent indication for coronary angiography and percutaneous
      coronary intervention (PCI) worldwide. PCI permit to reestablished coronary flow but
      effectiveness of PCI within thrombus containing lesions is limited by the risk of occurrence
      of distal embolization and no-reflow phenomenon. Distal embolization lead to coronary
      microcirculation lesions. This complication is related to poor prognosis.

      MGuard stent is a stainless-steel closed cell stent covered with an ultra-thin polymer mesh
      sleeve, which allows to prevent distal embolization during percutaneous coronary intervention
      in ST-segment-elevation myocardial infarction.

      Index of microcirculatory resistance (IMR) is a validated method to assess coronary
      microcirculation.

      Accordingly, the purpose of this study is to demonstrate that MGuard micronet mesh-covered
      stent prevent distal embolization and microvascular reperfusion impairment during primary
      PCI, compared with a bare metal stent (BMS) and drug eluting stent (DES) in patients with
      NSTE-ACS, assessed by Index of microcirculatory resistance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GUARDIANCORY study is a multicentre, prospective, randomized, non inferiority, open-label
      trial with a planned inclusion of 52 patients with STE and NSTE ACS and prescribed PCI.
      Patients will be randomized to benefiting either DES /BMS implantation (n=26) or MGuard stent
      (n=26) on the culprit lesion. Assessment of coronary microcirculation will be done by IMR
      immediately after PCI by using a pressure-temperature sensor-tipped coronary wire,
      thermodilution-derived.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Index of microcirculatory resistance (IMR)</measure>
    <time_frame>During the 2 hours after randomization</time_frame>
    <description>Index of microcirculatory resistance (IMR) will be measured with a pressure sensor/thermistor-tipped guidewire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TIMI flux on angiography</measure>
    <time_frame>During the 2 hours after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade blush on angiography</measure>
    <time_frame>During the 2 hours after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TIMI frame count measure</measure>
    <time_frame>During the 2 hours after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of risk area by BARI-Score</measure>
    <time_frame>During the 2 hours after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ST-segment resolution defined by &gt;70% ST-segment resolution on EKG post angioplasty compared to initial EKG</measure>
    <time_frame>During the 24 hours after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Enzymatic cycle with measure of troponin T and CPK pick</measure>
    <time_frame>7 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of wall motion score (WMS) by echocardiography</measure>
    <time_frame>2, 7 days after randomization, 6 month follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of 2D strain by echocardiography</measure>
    <time_frame>2, 7 days after randomization, 6 month follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiological follow up to detect intrastent restenosis</measure>
    <time_frame>6 month follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Coronary Disease</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Atherosclerosis</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>MGuard stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MGuard stent is a novel thin-strut metal stent with a polyethylene terephthalate micronet covering designed to trap and exclude thrombus and friable atheromatous debris to prevent distal embolization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug eluting stent and bare metal stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug eluting stent and bare metal stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MGuard stent</intervention_name>
    <description>MGuard micronet mesh-covered stent in treatment of STE and NSTE-ACS</description>
    <arm_group_label>MGuard stent</arm_group_label>
    <other_name>MGuard micronet mesh-covered stent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug eluting stent and bare metal stent</intervention_name>
    <description>Drug eluting stent and bare metal stent in treatment of STE and NSTE-ACS For example, Resolute Onyx</description>
    <arm_group_label>Drug eluting stent and bare metal stent</arm_group_label>
    <other_name>Resolute Onyx</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Patients affiliated to social security

          -  Patients with an NSTEMI or STEMI (1)

          -  Thrombus containing coronary lesions on angiography (TIMI thrombus grade ≥ 3)

          -  Eligible patients for revascularization with angioplasty

          -  Patients consenting to participate in the study.

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Prior myocardial infarction

          -  Prior CABG

          -  Inability to comply with the protocol

          -  Major patient protected by law (article L1121-8),

          -  Person deprived of liberty (article L1121-8),

          -  Pregnant woman

          -  Breastfeeding women

          -  Patient with terminal illness,

          -  Terminal Renal failure

          -  Allergy to iodine

          -  Adenosine's contraindications: Asthmatic patients, Second- or third-degree AV block
             without a pacemaker or sick sinus syndrome. Systolic blood pressure less than 90mmHg.
             Recent use of dipyridamole or dipyridamole-containing medications, Methyl xanthenes
             such as aminophylline caffeine or theobromine block the effect of adenosine and should
             be held for at least 12 hours prior to the test. Known hypersensitivity to adenosine.
             Unstable acute myocardial infarction or acute coronary syndrome.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles BARONE-ROCHETTE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Grenoble alpes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clémence CHARLON</last_name>
    <phone>+33476765933</phone>
    <email>ccharlon@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>anais ADOLLE</last_name>
    <email>aadolle@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Annecy Hospital</name>
      <address>
        <city>Annecy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loic BELLE, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Magalie PELLETIER</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles Barone-Rochette, MD, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Clémence CHARLON</last_name>
      <email>ccharlon@chu-grenoble.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S; ESC Scientific Document Group . 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016 Jan 14;37(3):267-315. doi: 10.1093/eurheartj/ehv320. Epub 2015 Aug 29.</citation>
    <PMID>26320110</PMID>
  </reference>
  <reference>
    <citation>Silen W, Machen TE, Forte JG. Acid-base balance in amphibian gastric mucosa. Am J Physiol. 1975 Sep;229(3):721-30.</citation>
    <PMID>2015</PMID>
  </reference>
  <reference>
    <citation>Pride YB, Mohanavelu S, Zorkun C, Kunadian V, Giugliano RP, Newby LK, Braunwald E, Califf RM, Harrington RA, Gibson CM; EARLY ACS Investigators. Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy. JACC Cardiovasc Interv. 2012 Sep;5(9):927-35. doi: 10.1016/j.jcin.2012.05.007.</citation>
    <PMID>22995880</PMID>
  </reference>
  <reference>
    <citation>Gibson CM, Kirtane AJ, Morrow DA, Palabrica TM, Murphy SA, Stone PH, Scirica BM, Jennings LK, Herrmann HC, Cohen DJ, McCabe CH, Braunwald E; TIMI Study Group. Association between thrombolysis in myocardial infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the randomized trial to evaluate the relative PROTECTion against post-PCI microvascular dysfunction and post-PCI ischemia among antiplatelet and antithrombotic agents-Thrombolysis In Myocardial Infarction 30 (PROTECT-TIMI 30). Am Heart J. 2006 Oct;152(4):756-61.</citation>
    <PMID>16996854</PMID>
  </reference>
  <reference>
    <citation>Gibson CM, de Lemos JA, Murphy SA, Marble SJ, McCabe CH, Cannon CP, Antman EM, Braunwald E; TIMI Study Group. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Circulation. 2001 May 29;103(21):2550-4.</citation>
    <PMID>11382722</PMID>
  </reference>
  <reference>
    <citation>De Bruyne B, Pijls NH, Smith L, Wievegg M, Heyndrickx GR. Coronary thermodilution to assess flow reserve: experimental validation. Circulation. 2001 Oct 23;104(17):2003-6.</citation>
    <PMID>11673336</PMID>
  </reference>
  <reference>
    <citation>Steg PG, Dabbous OH, Feldman LJ, Cohen-Solal A, Aumont MC, López-Sendón J, Budaj A, Goldberg RJ, Klein W, Anderson FA Jr; Global Registry of Acute Coronary Events Investigators. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Circulation. 2004 Feb 3;109(4):494-9. Epub 2004 Jan 26.</citation>
    <PMID>14744970</PMID>
  </reference>
  <reference>
    <citation>Cuisset T, Hamilos M, Melikian N, Wyffels E, Sarma J, Sarno G, Barbato E, Bartunek J, Wijns W, De Bruyne B. Direct stenting for stable angina pectoris is associated with reduced periprocedural microcirculatory injury compared with stenting after pre-dilation. J Am Coll Cardiol. 2008 Mar 18;51(11):1060-5. doi: 10.1016/j.jacc.2007.11.059.</citation>
    <PMID>18342222</PMID>
  </reference>
  <reference>
    <citation>Holm J, Häggendal E, Lundberg D, Scherstén T, Stenberg K, Wetterqvist H. Effect of lumbar sympathetic blockade and chlorpromazine-induced adrenergic alpha-receptor blockade on skin temperature in peripheral arterial diseases. J Cardiovasc Surg (Torino). 1976 Jan-Feb;17(1):69-71.</citation>
    <PMID>1398</PMID>
  </reference>
  <reference>
    <citation>Aarnoudse W, Fearon WF, Manoharan G, Geven M, van de Vosse F, Rutten M, De Bruyne B, Pijls NH. Epicardial stenosis severity does not affect minimal microcirculatory resistance. Circulation. 2004 Oct 12;110(15):2137-42. Epub 2004 Oct 4.</citation>
    <PMID>15466646</PMID>
  </reference>
  <reference>
    <citation>Nijveldt R, Beek AM, Hirsch A, Stoel MG, Hofman MB, Umans VA, Algra PR, Twisk JW, van Rossum AC. Functional recovery after acute myocardial infarction: comparison between angiography, electrocardiography, and cardiovascular magnetic resonance measures of microvascular injury. J Am Coll Cardiol. 2008 Jul 15;52(3):181-9. doi: 10.1016/j.jacc.2008.04.006.</citation>
    <PMID>18617066</PMID>
  </reference>
  <reference>
    <citation>Henriques JP, Zijlstra F, Ottervanger JP, de Boer MJ, van 't Hof AW, Hoorntje JC, Suryapranata H. Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction. Eur Heart J. 2002 Jul;23(14):1112-7.</citation>
    <PMID>12090749</PMID>
  </reference>
  <reference>
    <citation>Kaul P, Ezekowitz JA, Armstrong PW, Leung BK, Savu A, Welsh RC, Quan H, Knudtson ML, McAlister FA. Incidence of heart failure and mortality after acute coronary syndromes. Am Heart J. 2013 Mar;165(3):379-85.e2. doi: 10.1016/j.ahj.2012.12.005. Epub 2013 Jan 22.</citation>
    <PMID>23453107</PMID>
  </reference>
  <reference>
    <citation>Ng MK, Yeung AC, Fearon WF. Invasive assessment of the coronary microcirculation: superior reproducibility and less hemodynamic dependence of index of microcirculatory resistance compared with coronary flow reserve. Circulation. 2006 May 2;113(17):2054-61. Epub 2006 Apr 24.</citation>
    <PMID>16636168</PMID>
  </reference>
  <reference>
    <citation>Fearon WF, Balsam LB, Farouque HM, Caffarelli AD, Robbins RC, Fitzgerald PJ, Yock PG, Yeung AC. Novel index for invasively assessing the coronary microcirculation. Circulation. 2003 Jul 1;107(25):3129-32. Epub 2003 Jun 23. Erratum in: Circulation. 2003 Dec 23;108(25):3165.</citation>
    <PMID>12821539</PMID>
  </reference>
  <reference>
    <citation>Akdeniz C, Umman S, Nisanci Y, Umman B, Bugra Z, Aslanger EK, Kaplan A, Yilmaz A, Teker E, Güz G, Polat N, Sezer M. Percutaneous coronary intervention increases microvascular resistance in patients with non-ST-elevation acute coronary syndrome. EuroIntervention. 2013 Jun 22;9(2):228-34. doi: 10.4244/EIJV9I2A38.</citation>
    <PMID>23410633</PMID>
  </reference>
  <reference>
    <citation>Fearon WF, Shah M, Ng M, Brinton T, Wilson A, Tremmel JA, Schnittger I, Lee DP, Vagelos RH, Fitzgerald PJ, Yock PG, Yeung AC. Predictive value of the index of microcirculatory resistance in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2008 Feb 5;51(5):560-5. doi: 10.1016/j.jacc.2007.08.062.</citation>
    <PMID>18237685</PMID>
  </reference>
  <reference>
    <citation>Napodano M, Ramondo A, Tarantini G, Peluso D, Compagno S, Fraccaro C, Frigo AC, Razzolini R, Iliceto S. Predictors and time-related impact of distal embolization during primary angioplasty. Eur Heart J. 2009 Feb;30(3):305-13. doi: 10.1093/eurheartj/ehn594. Epub 2009 Jan 19.</citation>
    <PMID>19153179</PMID>
  </reference>
  <reference>
    <citation>Fearon WF, Low AF, Yong AS, McGeoch R, Berry C, Shah MG, Ho MY, Kim HS, Loh JP, Oldroyd KG. Prognostic value of the Index of Microcirculatory Resistance measured after primary percutaneous coronary intervention. Circulation. 2013 Jun 18;127(24):2436-41. doi: 10.1161/CIRCULATIONAHA.112.000298. Epub 2013 May 16.</citation>
    <PMID>23681066</PMID>
  </reference>
  <reference>
    <citation>Stone GW, Abizaid A, Silber S, Dizon JM, Merkely B, Costa RA, Kornowski R, Abizaid A, Wojdyła R, Maehara A, Dressler O, Brener SJ, Bar E, Dudek D. Prospective, Randomized, Multicenter Evaluation of a Polyethylene Terephthalate Micronet Mesh-Covered Stent (MGuard) in ST-Segment Elevation Myocardial Infarction: The MASTER Trial. J Am Coll Cardiol. 2012 Nov 6;60(19):1975-84. doi: 10.1016/j.jacc.2012.09.004.</citation>
    <PMID>23103033</PMID>
  </reference>
  <reference>
    <citation>Jolly SS, Cairns JA, Yusuf S, Meeks B, Pogue J, Rokoss MJ, Kedev S, Thabane L, Stankovic G, Moreno R, Gershlick A, Chowdhary S, Lavi S, Niemelä K, Steg PG, Bernat I, Xu Y, Cantor WJ, Overgaard CB, Naber CK, Cheema AN, Welsh RC, Bertrand OF, Avezum A, Bhindi R, Pancholy S, Rao SV, Natarajan MK, ten Berg JM, Shestakovska O, Gao P, Widimsky P, Džavík V; TOTAL Investigators. Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med. 2015 Apr 9;372(15):1389-98. doi: 10.1056/NEJMoa1415098. Epub 2015 Mar 16.</citation>
    <PMID>25853743</PMID>
  </reference>
  <reference>
    <citation>Napodano M, Dariol G, Al Mamary AH, Marra MP, Tarantini G, D'Amico G, Frigo AC, Buja P, Razzolini R, Iliceto S. Thrombus burden and myocardial damage during primary percutaneous coronary intervention. Am J Cardiol. 2014 May 1;113(9):1449-56. doi: 10.1016/j.amjcard.2014.01.423. Epub 2014 Feb 12.</citation>
    <PMID>24630783</PMID>
  </reference>
  <reference>
    <citation>Layland J, Carrick D, McEntegart M, Ahmed N, Payne A, McClure J, Sood A, McGeoch R, MacIsaac A, Whitbourn R, Wilson A, Oldroyd K, Berry C. Vasodilatory capacity of the coronary microcirculation is preserved in selected patients with non-ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv. 2013 Jun;6(3):231-6. doi: 10.1161/CIRCINTERVENTIONS.112.000180. Epub 2013 Jun 11.</citation>
    <PMID>23756697</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2016</study_first_submitted>
  <study_first_submitted_qc>March 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2017</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terephthalic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

